Spring Bank reports Phase II data for HBV candidate

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 treatment-naive patients with chronic HBV infection without cirrhosis in the first cohort of the Phase II ACHIEVE trial showing that once-daily 25 mg inarigivir soproxil (formerly SB 9200) significantly reduced HBV DNA, HBV RNA and hepatitis B s antigen (HBsAg) levels from baseline to week 12 vs. placebo. The Phase IIa portion of the double-blind, international trial is evaluating once-daily 25, 50, 100 and 200 mg doses of inarigivir for 12 weeks followed by Viread tenofovir disoproxil fumarate monotherapy for 12 weeks in 80 patients.

In 7 hepatitis B e antigen (HBeAg)-negative patients, 3 had undetectable HBV RNA levels at week 12, and 5 had undetectable HBV RNA levels at week 24. Inarigivir was well tolerated with no serious adverse events reported. Data were presented at the American Association for the Study of Liver Diseases meeting in Washington, D.C...